Patents by Inventor Aran Frank Labrijn

Aran Frank Labrijn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150353636
    Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved complement-dependent cytotoxicity (CDC).
    Type: Application
    Filed: January 10, 2013
    Publication date: December 10, 2015
    Inventors: Paul PARREN, Frank BEURSKENS, Rob N. DE JONG, Sandra VERPLOEGEN, Aran Frank LABRIJN, Janine SCHUURMAN
  • Publication number: 20150337049
    Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.
    Type: Application
    Filed: January 9, 2014
    Publication date: November 26, 2015
    Inventors: Aran Frank LABRIJN, Joyce MEESTERS, Joost J. NEIJSSEN, Edward Norbert VAN DEN BRINK, Janine SCHUURMAN, Paul PARREN
  • Publication number: 20150329642
    Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: May 26, 2015
    Publication date: November 19, 2015
    Inventors: Joost J. NEIJSSEN, Bart DE GOEIJ, Edward Norbert VAN DEN BRINK, Aran Frank LABRIJN, Rene HOET, Janine SCHUURMAN, Paul PARREN, Jan VAN DE WINKEL
  • Patent number: 9150663
    Abstract: Heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: October 6, 2015
    Assignee: GENMAB A/S
    Inventors: Aran Frank Labrijn, Joyce I. Meesters, Ewald T. J. Van Den Bremer, Joost J. Neijssen, Patrick Van Berkel, Bart De Goeij, Tom Vink, Jan Van De Winkel, Janine Schuurman, Paul Parren
  • Patent number: 9102733
    Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: August 11, 2015
    Assignee: Roche Palo Alto LLC
    Inventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van De Winkel, Martine Van Vugt
  • Patent number: 9085625
    Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: July 21, 2015
    Assignee: Genmab A/S
    Inventors: Aran Frank Labrijn, Stefan Loverix, Paul Parren, Jau Van De Winkel, Janine Schuurman, Lgnace Laster
  • Patent number: 9068011
    Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: June 30, 2015
    Assignee: GENMAB A+S
    Inventors: Joost J. Neijssen, Bart De Goeij, Edward Norbert Van Den Brink, Aran Frank Labrijn, Rene Hoet, Janine Schuurman, Paul Parren, Jan Van De Winkel
  • Publication number: 20150175707
    Abstract: The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.
    Type: Application
    Filed: July 5, 2013
    Publication date: June 25, 2015
    Inventors: Rob N. De Jong, Frank Beurskens, Paul Parren, Aran Frank Labrijn, Janine Schuurman, Arjen Vlug, Sandra Verploegen
  • Publication number: 20150004177
    Abstract: Isolated monoclonal antibodies which bind to human CD32b and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: June 27, 2014
    Publication date: January 1, 2015
    Inventors: Edward Norbert VAN DEN BRINK, Paul PARREN, Jan VAN DE WINKEL, Aran Frank LABRIJN, Frank Everhardus Martinus REBERS, Esther Cornelia Wilhelmina BREIJ
  • Publication number: 20140303356
    Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.
    Type: Application
    Filed: October 26, 2012
    Publication date: October 9, 2014
    Applicants: GENMAB A/S
    Inventors: Michael Gramer, Amitava Kundu, Ewald T. J. Van Den Bremer, Muriel Van Kamper, Patrick Priem, Aran Frank Labrijn, Joyce I. Meesters, Joost J. Neijssen, Janine Schuurman, Paul Parren, Patrick Van Berkel, Werner L. Vos, Arnout Gerritsen
  • Publication number: 20140242075
    Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
    Type: Application
    Filed: July 6, 2012
    Publication date: August 28, 2014
    Applicant: GENMAB B.V.
    Inventors: Paul Parren, Frank Beurskens, Rob N. De Jong, Aran Frank Labrijn, Janine Schuurman
  • Patent number: 8802089
    Abstract: Isolated monoclonal antibodies which bind to human CD32b and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: August 12, 2014
    Assignee: Genmab A/S
    Inventors: Edward Norbert Van Den Brink, Paul Parren, Jan Van De Winkel, Aran Frank Labrijn, Frank Everhardus Martinus Rebers, Esther Cornelia Wilhelmina Breij
  • Publication number: 20140170148
    Abstract: Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.
    Type: Application
    Filed: April 20, 2012
    Publication date: June 19, 2014
    Applicant: GENMAB A/S
    Inventors: Bart De Goeij, Patrick Van Berkel, Kristin Strumane, Aran Frank Labrijn, Joost J. Neijssen, Joyce I. Meesters, Paul Parren, Janine Schuurman
  • Publication number: 20140170149
    Abstract: Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed.
    Type: Application
    Filed: April 20, 2012
    Publication date: June 19, 2014
    Applicant: GENMAB A/S
    Inventors: Joost J. Neijssen, Joyce I. Meesters, Bart De Goeij, Aran Frank Labrijn, Paul Parren, Janine Schuurman
  • Publication number: 20130216548
    Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: March 10, 2011
    Publication date: August 22, 2013
    Applicant: GENMAB A/S
    Inventors: Joost J. Neijssen, Bart De Goeij, Edward Norbert Van Den Brink, Aran Frank Labrijn, Rene Hoet, Janine Schuurman, Paul Parren, Jan Van De Winkel
  • Publication number: 20130189271
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related anti-body-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: May 27, 2011
    Publication date: July 25, 2013
    Applicant: GENMAB A/S
    Inventors: Bart De Goeij, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, Jan Van De Winkel, David Satijn, Paul Parren, Aran Frank Labrijn, Joyce I. Meesters, Janine Schuurman, Edward Norbert Van Den Brink
  • Publication number: 20130039913
    Abstract: Heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.
    Type: Application
    Filed: April 20, 2011
    Publication date: February 14, 2013
    Applicant: GENMAB A/S
    Inventors: Aran Frank Labrijn, Joyce I. Meesters, Ewald T. J. Van Den Bremer, Joost J. Neijssen, Patrick Van Berkel, Bart De Goeij, Tom Vink, Jan Van De Winkel, Janine Schuurman, Paul Parren
  • Publication number: 20120020952
    Abstract: The invention relates to a method for producing a mixture comprising two or more different antibodies in a single recombinant host cell. In one embodiment, a mixture of different monovalent antibodies is produced. In another embodiment, a mixture of monovalent and bivalent antibodies is produced. The invention also relates to mixtures of antibodies obtainable by the method of the invention and to light chain sequences that are particularly useful in the method of the invention.
    Type: Application
    Filed: January 26, 2010
    Publication date: January 26, 2012
    Applicant: GENMAB A/S
    Inventors: Paul Parren, Joost J. Neijssen, Aran Frank Labrijn, Janine Schuurman, Tom Vink, Jan Van De Winkel, Stefan Loverix, Ignace Lasters
  • Publication number: 20110293607
    Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.
    Type: Application
    Filed: December 3, 2009
    Publication date: December 1, 2011
    Inventors: Aran Frank Labrijn, Stefan Loverix, Paul Parren, Jau Van De Winkel, Janine Schuurman, Lgnace Laster
  • Publication number: 20110086366
    Abstract: The invention relates to methods and kits for assessing the risk, for an individual, of developing an adverse event upon treatment with a therapeutic antibody which is capable of Fab-arm exchange, said method comprising the steps of: a) providing a sample from an individual who is a candidate for treatment with said therapeutic antibody, b) assaying said sample for the presence of circulating IgG4 antibodies that binds an antigen known or suspected to be associated with a causative agent of said adverse event, and c) assessing, on the basis of the outcome of the assay of step b), the risk that the individual will develop said adverse event upon treatment with the therapeutic antibody, wherein the risk of development of said adverse event increases with increased level of said circulating IgG4 antibodies.
    Type: Application
    Filed: February 20, 2009
    Publication date: April 14, 2011
    Applicant: GENMAB A/S
    Inventors: Aran Frank Labrijn, Janine Schuurman, Jan Van De Winkel, Paul Parren